Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

PURPOSE: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19(+) B-cell malignancies. PATIENTS AND METHODS: We treated 15 patients with advance...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Kochenderfer, James N., Dudley, Mark E., Kassim, Sadik H., Somerville, Robert P.T., Carpenter, Robert O., Stetler-Stevenson, Maryalice, Yang, James C., Phan, Giao Q., Hughes, Marybeth S., Sherry, Richard M., Raffeld, Mark, Feldman, Steven, Lu, Lily, Li, Yong F., Ngo, Lien T., Goy, Andre, Feldman, Tatyana, Spaner, David E., Wang, Michael L., Chen, Clara C., Kranick, Sarah M., Nath, Avindra, Nathan, Debbie-Ann N., Morton, Kathleen E., Toomey, Mary Ann, Rosenberg, Steven A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2015
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322257/
https://ncbi.nlm.nih.gov/pubmed/25154820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.2025
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller